U24CA272450

Metabolic dysregulation and cancer risk program: Coordinating Center - Project Summary

The goal of the Metabolic Dysregulation and Cancer Risk Consortium (MDCRC) is to identify tangible mechanistic/etiological pathways that link obesity-related metabolic dysregulation with cancer risk to inform cancer prevention strategies. The consortium proposes to accomplish this through developing common measures for obesity-related metabolic dysregulation for different cancer types, understanding how obesity-related metabolic dysregulation affects cancer initiation and development, characterizing signal cross-talk between key biologic processes that impact obesity-associated metabolic dysregulation and cancer risk, and determining the utility of emerging approaches for the discovery of novel obesity-associated metabolic targets in cancer risk and prevention.

The Biostatistics Center (Center) in the Milken Institute School of Public Health (SPH) of the George Washington University (GW), the participating institution, proposes to serve as the MDCRC Coordinating Center (CC). The MDCRC CC will integrate this expertise and experience, drawing upon our successful history of coordinating center leadership in collaborative research consortia, capacity for innovation, and the extensive scientific expertise in obesity and cancer prevention, nutrition, exercise, metabolism, body composition, and bioinformatics/computational biology to form a CC that is rooted in scientific rigor and is flexible and responsive to the diverse challenges and scientific opportunities of the MDCRC.

The specific aims of the MDCRC include to:
1) Provide scientific leadership and project management for collaborative cross-consortium activities, including providing guidance on the selection of common measures and development of consistent protocols and manuals of operations, maintain private and public websites, establishing topical work groups, and spearhead outreach activities.
2) Facilitate data harmonization, data sharing, and results dissemination across the MDCRC sites and with NCI, including identification of opportunities for novel data collection to enrich the MDCRC data resources, developing a common data management platform, and training for site staff.
3) Establish a self-evaluation core to promote timely self-evaluation, along with effective self-correcting actions, working with NCI and the consortium investigators to establish criteria and outputs related to the "success" of individual investigators, study teams, and consortium sites.

George Washington University (The)

TO IDENTIFY CANCER RISKS AND RISK REDUCTION STRATEGIES, TO IDENTIFY FACTORS THAT CAUSE CANCER IN HUMANS, AND TO DISCOVER AND DEVELOP MECHANISMS FOR CANCER PREVENTION AND PREVENTIVE INTERVENTIONS IN HUMANS. RESEARCH PROGRAMS INCLUDE: (1) CHEMICAL, PHYSICAL AND MOLECULAR CARCINOGENESIS, (2) SCREENING, EARLY DETECTION AND RISK ASSESSMENT, INCLUDING BIOMARKER DISCOVERY, DEVELOPMENT AND VALIDATION, (3) EPIDEMIOLOGY, (4) NUTRITION AND BIOACTIVE FOOD COMPONENTS, (5) IMMUNOLOGY AND VACCINES, (6) FIELD STUDIES AND STATISTICS, (7) CANCER CHEMOPREVENTION AND INTERCEPTION, (8) PRE-CLINICAL AND CLINICAL AGENT DEVELOPMENT, (9) ORGAN SITE STUDIES AND CLINICAL TRIALS, (10) HEALTH-RELATED QUALITY OF LIFE AND PATIENT-CENTERED OUTCOMES, AND (11) SUPPORTIVE CARE AND MANAGEMENT OF SYMPTOMS AND TOXICITIES. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO STIMULATE TECHNICAL INNOVATION, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, AND FOSTER PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS.

93.393 - Cancer Cause and Prevention Research

National Cancer Institute (NCI) [HHS - NIH]

Rockville, Maryland 208523943 United States

Single Zip Code

Coordinating Center for the Metabolic Dysregulation and Cancer Risk Program: A Transdisciplinary Approach to Obesity-Associated Cancer Research (U24 Clinical Trial Not Allowed) (RFA-CA-21-022)

Amendment Since initial award the total obligations have increased 237% from $625,223 to $2,105,528.